


TOOLS FOR A HOLISTIC ASSESSMENT OF ATOPIC DERMATITIS ACROSS AGE GROUPS UPDATED 2022

The Broad and Interrelated Burdens of AD Have Given Rise to Multiple Assessment Approaches in Adults



Clinical signs

EASI¹

IGA²

SCORAD³

BSA⁴



Symptoms

POEM¹¹

Itch NRS-11^{12,13}

PO-SCORAD¹⁴

ItchyQoL⁶

Itch VAS³



Quality of life

DLQI⁵

ItchyQoL⁶

Skindex-29⁷

QoLIAD⁸

EQ-5D⁹

SF-12¹⁰



Long-term disease control

ADCT^{15,16}

RECAP¹⁵⁻¹⁷



Mental health




HADS¹⁸

AD, atopic dermatitis; ADCT, Atopic Dermatitis Control Tool; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema and Severity Index; EQ-5D, EuroQoL 5-dimension questionnaire; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator's Global Assessment; NRS, Numerical Rating Scale; POEM, Patient-Oriented Eczema Measure; PO-SCORAD, Patient-Oriented SCORAD; QoL, quality of life; RECAP, a patient-reported outcome measure of eczema control; SCORAD, SCORing Atopic Dermatitis; SF-12, Short Form 12; VAS, visual analog scale.

1. Hanifin JM, et al. *Exp Dermatol*. 2001;10:11-18. 2. Rehal B, Armstrong A. *PLoS One*. 2011;6:e17520. 3. ETFAD. *Dermatology*. 1993;186:23-31. 4. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321. 5. Basra MK, et al. *Dermatology*. 2015;230:27-33. 6. Zeidler C, et al. *J Eur Acad Dermatol Venereol*. 2019;33(2):391-397. 7. Chren MM, et al. *Dermatol Clin*. 2012;30(2):231-236. 8. Whalley D, et al. *Br J Dermatol*. 2004;150(2):274-283. 9. EUROQOL. <https://euroqol.org/publications/>. Accessed October 2022. 10. Ware J, et al. *Medical Care*. 1996;34(3):220-233. 11. Charman CR, et al. *Arch Dermatol*. 2004;140:1513-1519. 12. Reich A, et al. *Acta Derm Venereol*. 2016;96:978-980. 13. Pereira MP, et al. *Itch*. 2019;4:e29. 14. Stalder JF, et al. *Allergy*. 2011;66(8):1114-1121. 15. Harmonising Outcome Measures for Eczema. <http://www.homeforeczema.org/>. Accessed October 2022. 16. Williams HC, et al. *J Allergy Clin Immunol*. 2022;149(6):1899-1911. 17. Bhanot A, et al. *Clin Exp Dermatol*. 2022;47(2):440-442. 18. Bjelland I, et al. *J Psychosom Res*. 2002;52:69-77.

The Broad and Interrelated Burdens of AD Have Given Rise to Multiple Assessment Approaches in Adults



Clinical signs

EASI¹

IGA²

SCORAD³

BSA⁴



Symptoms

POEM¹¹

Itch NRS-11^{12,13}

PO-SCORAD¹⁴

ItchyQoL⁶

Itch VAS³



Quality of life

DLQI⁵

ItchyQoL⁶

Skindex-29⁷

QoLIAD⁸

EQ-5D⁹

SF-12¹⁰



Long-term disease control

ADCT^{15,16}

RECAP¹⁵⁻¹⁷



Mental health



HADS¹⁸

Tools adopted by
HOME
consensus^{15,16}

AD, atopic dermatitis; ADCT, Atopic Dermatitis Control Tool; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema and Severity Index; EQ-5D, EuroQoL 5-dimension questionnaire; HADS, Hospital Anxiety and Depression Scale; HOME, Harmonising Outcome Measures for Eczema; IGA, Investigator's Global Assessment; NRS, Numerical Rating Scale; POEM, Patient-Oriented Eczema Measure; PO-SCORAD, Patient-Oriented SCORAD; QoL, quality of life; RECAP, a patient-reported outcome measure of eczema control; SCORAD, SCORING Atopic Dermatitis; SF-12, Short Form 12; VAS, visual analog scale.

1. Hanifin JM, et al. *Exp Dermatol*. 2001;10:11-18. 2. Rehal B, Armstrong A. *PLoS One*. 2011;6:e17520. 3. ETFAD. *Dermatology*. 1993;186:23-31. 4. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321. 5. Basra MK, et al. *Dermatology*. 2015;230:27-33. 6. Zeidler C, et al. *J Eur Acad Dermatol Venereol*. 2019;33(2):391-397. 7. Chren MM, et al. *Dermatol Clin*. 2012;30(2):231-236. 8. Whalley D, et al. *Br J Dermatol*. 2004;150(2):274-283. 9. EUROQOL. <https://euroqol.org/publications/>. Accessed October 2022. 10. Ware J, et al. *Medical Care*. 1996;34(3):220-233. 11. Charman CR, et al. *Arch Dermatol*. 2004;140:1513-1519. 12. Reich A, et al. *Acta Derm Venereol*. 2016;96:978-980. 13. Pereira MP, et al. *Itch*. 2019;4:e29. 14. Stalder JF, et al. *Allergy*. 2011;66(8):1114-1121. 15. Harmonising Outcome Measures for Eczema. <http://www.homeforeczema.org/>. Accessed October 2022. 16. Williams HC, et al. *J Allergy Clin Immunol*. 2022;149(6):1899-1911. 17. Bhanot A, et al. *Clin Exp Dermatol*. 2022;47(2):440-442. 18. Bjelland I, et al. *J Psychosom Res*. 2002;52:69-77.

For Pediatric Patients, Specific Assessment Tools Have Been Developed or Adapted From Tools Used in Adults



Clinical signs

EASI¹

SCORAD²

IGA³

BSA⁴



Symptoms

POEM⁹

PO-SCORAD¹⁰

Tween/Kids ItchyQoL⁶

Itch VAS²



Quality of life

CDLQI, IDQOL⁵

Tween/Kids ItchyQoL⁶

Skindex-Teen⁷

EQ-5D-Y⁸



Long-term disease control

ADCT^{5,11,12}

RECAP^{5,11,13}

WCWs¹⁴



Mental health




SDQ¹⁵
RCADS¹⁶
PROMIS¹⁷

Tools adopted by
HOME
consensus^{5,11}

ADCT, Atopic Dermatitis Control Tool; BSA, body surface area; CDLQI, Children's Dermatology Life Quality Index; EASI, Eczema and Severity Index; EQ-5D, EuroQoL 5-dimension questionnaire; HOME, Harmonising Outcome Measures for Eczema; IDQOL, Infants' Dermatitis Quality of Life Index; IGA, Investigator's Global Assessment; POEM, Patient-Oriented Eczema Measure; PO-SCORAD, Patient-Oriented SCORAD; PROMIS, Patient-Reported Outcomes Measurement Information System; QoL, quality of life; RCADS, Revised Child Anxiety and Depression Scale; RECAP, a patient-reported outcome measure of eczema control; SCORAD, SCORing Atopic Dermatitis; SDQ, Strengths and Difficulties Questionnaire; VAS, visual analog scale; WCW, Well-Controlled Week.

1. Hanifin JM, et al. *Exp Dermatol*. 2001;10:11-18. 2. ETFAD. *Dermatology*. 1993;186:23-31. 3. Rehal B, Armstrong A. *PLoS One*. 2011;6:e17520. 4. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321. 5. Harmonising Outcome Measures for Eczema. <http://www.homeforeczema.org/>. Accessed October 2022. 6. Greb E. *Dermatology News*. <https://www.mdedge.com/dermatology/article/195501/pediatrics/pediatric-pruritus-requires-distinct-approach-assessment-and>. Accessed October 2022. 7. Smidt AC, et al. *Arch Dermatol*. 2010;146:865-869. 8. EUROQOL. <https://euroqol.org/publications/>. Accessed October 2022. 9. Charman CR, et al. *Arch Dermatol*. 2004;140:1513-1519. 10. Stalder JF, et al. *Allergy*. 2011;66(8):1114-1121. 11. Williams HC, et al. *J Allergy Clin Immunol*. 2022;149(6):1899-1911. 12. ADCT terms of use. <https://www.adcontroltool.com/adct-how-to-use1>. Accessed October 2022. 13. Bhanot A, et al. *Clin Exp Dermatol*. 2022;47(2):440-442. 14. Langan SM, et al. *J Allergy Clin Immunol*. 2017;140:1580-1586. 15. Strengths and difficulties questionnaire (SDQ). https://depts.washington.edu/dbpeds/Screening%20Tools/Strengths_and_Difficulties_Questionnaire.pdf. Accessed October 2022. 16. Klaukus L, et al. *BMC Psychiatry*. 2020;20(1):47. 17. Irwin DE, et al. *Qual Life Res*. 2010;19(4):595-607.

Many of These Tools are Designed for Specific Age Ranges to Account for Their Unique Needs



ADCT, Atopic Dermatitis Control Tool; CDLQI, Children's Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; IDQOL, Infants' Dermatitis Quality of Life Index; POEM, Patient-Oriented Eczema Measure; QoL, quality of life; RECAP, a patient-reported outcome measure of eczema control; SCORAD, SCORing Atopic Dermatitis; SDQ, Strengths and Difficulties Questionnaire; WCW, Well-Controlled Week.

1. Hanifin JM, et al. *Exp Dermatol*. 2001;10:11-18. 2. Charman CR, et al. *Arch Dermatol*. 2004;140:1513-1519. 3. ETFAD. *Dermatology*. 1993;186:23-31. 4. Greb E. *Dermatology News*. <https://www.mdedge.com/dermatology/article/195501/pediatrics/pediatric-pruritus-requires-distinct-approach-assessment-and>. Accessed October 2022. 5. Harmonising Outcome Measures for Eczema. <http://www.homeforeczema.org/> Accessed October 2022. 6. Cardiff University. Children's Dermatology Life Quality Index. <https://www.cardiff.ac.uk/medicine/resources/quality-of-life-questionnaires/childrens-dermatology-life-quality-index>. Accessed November 2022. 7. Cardiff University. Infants' Dermatitis Quality of Life Index. <https://www.cardiff.ac.uk/medicine/resources/quality-of-life-questionnaires/infants-dermatitis-quality-of-life-index>. Accessed November 2022. 8. Smidt AC, et al. *Arch Dermatol*. 2010;146:865-869. 9. Pariser DM, et al. *Curr Med Res Opin*. 2020;36(3):367-376. 10. Simpson E, et al. *BMC Dermatology*. 2019;19:15. 11. ADCT terms of use. <https://www.adcontroltool.com/adct-how-to-use1> Accessed October 2022. 12. Howells L, et al. *Br J Dermatol*. 2020;183(3):524-536. 13. Langan SM, et al. *J Allergy Clin Immunol*. 2017;140:1580-1586. 14. Strengths and difficulties questionnaire (SDQ). https://depts.washington.edu/dbpeds/Screening%20Tools/Strengths_and_Difficulties_Questionnaire.pdf. Accessed October 2022.

Introducing George – A 24-year-old Patient With AD

"Male, age 24 years"



Introducing George – A 24-year-old Patient With AD



"Male, age 24 years"

History

- George is a professional musician, playing keyboard in a jazz band several nights a week
- Atopic dermatitis since he was one year old
- Continuous flare-ups linked to sweating

Introducing George – A 24-year-old Patient With AD



"Male, age 24 years"

History

- George is a professional musician, playing keyboard in a jazz band several nights a week
- Atopic dermatitis since he was one year old
- Continuous flare-ups linked to sweating

Topical and UV therapy

- Several courses of topical treatments per year:
 - Corticosteroids
 - Tacrolimus
- He was treated with phototherapy (UVBnb) during adolescence

EASI Assesses the Extent and Severity of AD Signs



Body Regions

Head & neck

Upper limbs

Trunk (including genital area)

Lower limbs (including buttocks)

Note: Does not take into account dryness or scaling.

AD, atopic dermatitis; E, erythema; EASI, Eczema Area and Severity Index; Ex, excoriation; I, induration/papulation; L, lichenification.

1Hanifin JM, et al. *Exp Dermatol*. 2001;10(1):11-18.

EASI Assesses the Extent and Severity of AD Signs



Body Regions

Head & neck

Upper limbs

Trunk (including genital area)

Lower limbs (including buttocks)

Area score

Area score	% of affected skin
0	No eczema
1	1–9%
2	10–29%
3	30–49%
4	50–69%
5	70–89%
6	90–100%

Note: Does not take into account dryness or scaling.
AD, atopic dermatitis; E, erythema; EASI, Eczema Area and Severity Index; Ex, excoriation; I, induration/papulation; L, lichenification.
1Hanifin JM, et al. *Exp Dermatol*. 2001;10(1):11-18.

EASI Assesses the Extent and Severity of AD Signs



Body Regions

Head & neck

Upper limbs

Trunk (including genital area)

Lower limbs (including buttocks)

Area score

Area score	% of affected skin
0	No eczema
1	1–9%
2	10–29%
3	30–49%
4	50–69%
5	70–89%
6	90–100%

Severity score (0–3 score each)

Key signs
1. Erythema
2. Induration/papulation/edema
3. Excoriation
4. Lichenification

Note: Does not take into account dryness or scaling.
AD, atopic dermatitis; E, erythema; EASI, Eczema Area and Severity Index; Ex, excoriation; I, induration/papulation; L, lichenification.
1Hanifin JM, et al. *Exp Dermatol*. 2001;10(1):11-18.

EASI Assesses the Extent and Severity of AD Signs



Body Regions

Head & neck

Upper limbs

Trunk (including genital area)

Lower limbs (including buttocks)

Area score		Severity score (0–3 score each)	
Area score	% of affected skin	Key signs	
0	No eczema	1. Erythema	
1	1–9%	2. Induration/papulation/edema	
2	10–29%	3. Excoriation	
3	30–49%	4. Lichenification	
4	50–69%		
5	70–89%		
6	90–100%		
Body region		EASI score	
Head/neck		$(E + I + Ex + L) \times \text{area} \times 0.1$	
Upper limbs		$(E + I + Ex + L) \times \text{area} \times 0.2$	
Trunk		$(E + I + Ex + L) \times \text{area} \times 0.3$	
Lower limbs		$(E + I + Ex + L) \times \text{area} \times 0.4$	
EASI		Sum of the above 4 body region scores	

Note: Does not take into account dryness or scaling.
AD, atopic dermatitis; E, erythema; EASI, Eczema Area and Severity Index; Ex, excoriation; I, induration/papulation; L, lichenification.
1Hanifin JM, et al. *Exp Dermatol*. 2001;10(1):11-18.

EASI Assesses the Extent and Severity of AD Signs^{1,2}



Body Regions

Head & neck

Upper limbs

Trunk (including genital area)

Lower limbs (including buttocks)

Maximum score

72

0.1–7 = mild²
>7–21 = moderate²
>21 = severe²

Area score

Area score	% of affected skin
0	No eczema
1	1–9%
2	10–29%
3	30–49%
4	50–69%
5	70–89%
6	90–100%

Severity score (0–3 score each)

Key signs
1. Erythema
2. Induration/papulation/edema
3. Excoriation
4. Lichenification

Body region	EASI score
Head/neck	(E + I + Ex + L) x area x 0.1
Upper limbs	(E + I + Ex + L) x area x 0.2
Trunk	(E + I + Ex + L) x area x 0.3
Lower limbs	(E + I + Ex + L) x area x 0.4
EASI	Sum of the above 4 body region scores

Note: Does not take into account dryness or scaling.
AD, atopic dermatitis; E, erythema; EASI, Eczema Area and Severity Index; Ex, excoriation; I, induration/papulation; L, lichenification.
1. Hanifin JM, et al. *Exp Dermatol*. 2001;10(1):11-18. 2. Hanifin JM, et al. *Dermatitis*. 2022;33(3):187-192.

Note That Presentation of Signs may Differ in Patients With Skin of Color¹⁻⁴



Photo is not representative of all patients with atopic dermatitis and is used with permission from Sanofi Genzyme and Regeneron.

1. Mei-Yen Yong A, Tay YK. *Dermatol Clin*. 2017;35:395-402.
2. Zhao CY, et al. *Br J Dermatol*. 2017;176(3):985-992.
3. Sangha AM. *J Clin Aesthet Dermatol*. 2021;14(3 Suppl 1):S20-S22.
4. Aoki V, et al. *Dermatitis*. 2022 Epub Mar 22. doi: 10.1097/DER.0000000000000864.

Note That Presentation of Signs may Differ in Patients With Skin of Color¹⁻⁴



- Lesions on the extensor surfaces rather than traditional flexural lesions¹⁻⁴

Photo is not representative of all patients with atopic dermatitis and is used with permission from Sanofi Genzyme and Regeneron.

1. Mei-Yen Yong A, Tay YK. *Dermatol Clin*. 2017;35:395-402. 2. Zhao CY, et al. *Br J Dermatol*. 2017;176(3):985-992. 3. Sangha AM. *J Clin Aesthet Dermatol*. 2021;14(3 Suppl 1):S20-S22. 4. Aoki V, et al. *Dermatitis*. 2022 Epub Mar 22. doi: 10.1097/DER.0000000000000864.

Note That Presentation of Signs may Differ in Patients With Skin of Color¹⁻⁴



- Lesions on the extensor surfaces rather than traditional flexural lesions¹⁻⁴
- Erythema may appear violaceous and less obvious¹⁻⁴

Photo is not representative of all patients with atopic dermatitis and is used with permission from Sanofi Genzyme and Regeneron.

1. Mei-Yen Yong A, Tay YK. *Dermatol Clin*. 2017;35:395-402. 2. Zhao CY, et al. *Br J Dermatol*. 2017;176(3):985-992. 3. Sangha AM. *J Clin Aesthet Dermatol*. 2021;14(3 Suppl 1):S20-S22. 4. Aoki V, et al. *Dermatitis*. 2022 Epub Mar 22. doi: 10.1097/DER.0000000000000864.

Note That Presentation of Signs may Differ in Patients With Skin of Color¹⁻⁴



- Lesions on the extensor surfaces rather than traditional flexural lesions¹⁻⁴
- Erythema may appear violaceous and less obvious¹⁻⁴
- Primary phenotype may be follicular, papular, or lichenoid eczema¹⁻⁴
- Persistent dyschromia or pigmentary alterations are more pronounced when AD lesions resolve^{1,3}

Photo is not representative of all patients with atopic dermatitis and is used with permission from Sanofi Genzyme and Regeneron.

AD, atopic dermatitis.

1. Mei-Yen Yong A, Tay YK. *Dermatol Clin*. 2017;35:395-402. 2. Zhao CY, et al. *Br J Dermatol*. 2017;176(3):985-992. 3. Sangha AM. *J Clin Aesthet Dermatol*. 2021;14(3 Suppl 1):S20-S22.

4. Aoki V, et al. *Dermatitis*. 2022 Epub Mar 22. doi: 10.1097/DER.0000000000000864.

George’s EASI Score Indicates That his AD Disease is Moderate in Severity^{1,2}



EASI score

18.3

Body region	EASI score
Head/neck	(E + I + Ex + L) x area x 0.1
Upper limbs	(E + I + Ex + L) x area x 0.2
Trunk	(E + I + Ex + L) x area x 0.3
Lower limbs	(E + I + Ex + L) x area x 0.4

Case based on hypothetical patient.

AD, atopic dermatitis; EASI, Eczema Area and Severity Index.

1. Hanifin JM, et al. *Exp Dermatol*. 2001;10(1):11-18. 2. Hanifin JM, et al. *Dermatitis*. 2022;33(3):187-192.

George's EASI Score Indicates That his AD Disease is Moderate in Severity¹



EASI score

18.3

0.1–7 = mild²
>7–21 = moderate
>21 = severe

Body region	EASI score
Head/neck	$(E + I + Ex + L) \times \text{area} \times 0.1$
Upper limbs	$(E + I + Ex + L) \times \text{area} \times 0.2$
Trunk	$(E + I + Ex + L) \times \text{area} \times 0.3$
Lower limbs	$(E + I + Ex + L) \times \text{area} \times 0.4$

Case based on hypothetical patient.

AD, atopic dermatitis; EASI, Eczema Area and Severity Index.

1. Hanifin JM, et al. *Exp Dermatol*. 2001;10(1):11-18. 2. Hanifin JM, et al. *Dermatitis*. 2022;33(3):187-192.

SCORAD Assesses Signs of AD as Well as Pruritus and Sleep Loss^{1,2}




AD, atopic dermatitis; SCORAD, SCORing Atopic Dermatitis.

1. ETFAD. *Dermatology*. 1993;186(1):23-31. 2. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321.

SCORAD Assesses Signs of AD as Well as Pruritus and Sleep Loss^{1,2}

A. Extent¹



A score:

SCORAD Assesses Signs of AD as Well as Pruritus and Sleep Loss^{1,2}

A. Extent¹



A score:

B. Intensity^{1,2}

Criteria	Intensity
Erythema	
Edema/papulation	
Oozing/crust	
Excoriation	
Lichenification	
Dryness (uninvolved areas)	

Means of calculation

- 0=absence
- 1=mild
- 2=moderate
- 3=severe

B score:

AD, atopic dermatitis; SCORAD, SCORing Atopic Dermatitis.
1. ETFAD. *Dermatology*. 1993;186(1):23-31. 2. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321.

SCORAD Assesses Signs of AD as Well as Pruritus and Sleep Loss^{1,2}

A. Extent¹



A score:

B. Intensity^{1,2}

Criteria	Intensity
Erythema	
Edema/papulation	
Oozing/crust	
Excoriation	
Lichenification	
Dryness (uninvolved areas)	

Means of calculation

0=absence

1=mild

2=moderate

3=severe

B score:

C. Subjective symptoms Pruritus + Sleep loss¹

Visual analog scale
(0–10: average for
the last 3 days or nights)

C score: Pruritus


+

C score: Sleep loss

AD, atopic dermatitis; SCORAD, SCORing Atopic Dermatitis.
1. ETFAD. *Dermatology*. 1993;186(1):23-31. 2. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321.

SCORAD Assesses Signs of AD as Well as Pruritus and Sleep Loss^{1,2}

A. Extent¹



A score:

B. Intensity^{1,2}

Criteria	Intensity
Erythema	
Edema/papulation	
Oozing/crust	
Excoriation	
Lichenification	
Dryness (uninvolved areas)	

Means of calculation

0=absence

1=mild

2=moderate

3=severe

B score:

C. Subjective symptoms Pruritus + Sleep loss¹

Visual analog scale
(0–10: average for
the last 3 days or nights)

C score: Pruritus

+

C score: Sleep loss

SCORAD = A/5 + 7B/2 + C¹
maximum score=103
<25=mild; >25–50=moderate; >50=severe

George's SCORAD Score Indicates That his AD is Severe^{1,2}



SCORAD score

58.3

A. Extent of disease

22.5

B. Intensity items

10

- Erythema = 2
- Edema/papulation = 1
- Oozing/crusts = 1
- Excoriations = 2
- Lichenification = 1
- Dryness = 3

C. Subjective symptoms

18.8

- Pruritus = 9.8
- Sleep loss = 9

$$\left[\text{SCORAD score} = \frac{22.5}{5} + \frac{7 \times 10}{2} + 18.8 \right]$$

Case based on hypothetical patient.

AD, atopic dermatitis; SCORAD, SCORing Atopic Dermatitis.

1. ETFAD. *Dermatology*. 1993;186(1):23-31. 2. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321.

George's SCORAD Score Indicates That his AD is Severe^{1,2}



A. Extent of disease

22.5

B. Intensity items

10

- Erythema = 2
- Edema/papulation = 1
- Oozing/crusts = 1
- Excoriations = 2
- Lichenification = 1
- Dryness = 3

C. Subjective symptoms

18.8

- Pruritus = 9.8
- Sleep loss = 9

SCORAD score

58.3

<25=mild

>25–50=moderate

>50=severe

$$\text{SCORAD score} = \frac{22.5}{5} + \frac{7 \times 10}{2} + 18.8$$

Case based on hypothetical patient.

AD, atopic dermatitis; SCORAD, SCORing Atopic Dermatitis.

1. ETFAD. *Dermatology*. 1993;186(1):23-31. 2. Chopra R, et al. *Br J Dermatol*. 2017;177(5):1316-1321.

Using the Peak Pruritus NRS, George Rated his Worst Itch as 9 out of 10 Over the Previous 24 Hours



Worst itch over previous 24 hours

0 1 2 3 4 5 6 7 8 9 10

Numerical Rating Scale (NRS)

ASSESSMENTS

Pruritus

Sleep disturbance

Quality of life

Using the Peak Pruritus NRS, George Rated his Worst Itch as 9 out of 10 Over the Previous 24 Hours



Worst itch over previous 24 hours

0 1 2 3 4 5 6 7 8 9 10

Numerical Rating Scale (NRS)

Peak Pruritus NRS

9

ASSESSMENTS

Pruritus


Sleep disturbance

Quality of life

But With SCORAD VAS, George Rated his Itch as 9.9 Over the Last 3 Days – Almost “Worst Itch Imaginable”



SCORAD VAS Itch



George's score

9.9

ASSESSMENTS

Pruritus


Sleep disturbance

Quality of life

But With SCORAD VAS, George Rated his Itch as 9.9 Over the Last 3 Days – Almost “Worst Itch Imaginable”



SCORAD VAS Itch



George's score

9.9

SCORAD VAS Sleep Loss



George's score

9

ASSESSMENTS

Pruritus

Sleep disturbance

Quality of life

POEM Uses Self-assessment of the Frequency of Symptoms Identified by Patients to be Most Important

POEM: Patient-Oriented Eczema Measure (range 0–28)

Over the last week, on how many days has your skin been...

1. Itchy?
2. Bleeding?
3. Weeping or oozing?
4. Cracked?
5. Flaked off?
6. Dry or rough?
7. Over the last week, on how many days has your sleep been disturbed?

POEM Uses Self-assessment of the Frequency of Symptoms Identified by Patients to be Most Important



POEM: Patient-Oriented Eczema Measure (range 0–28)

Over the last week, on how many days has your skin been...

1. Itchy?

2. Bleeding?

3. Weeping or oozing?

4. Cracked?
5. Flaked off?

6. Dry or rough?

7. Over the last week, on how many days has your sleep been disturbed?

Response	No days	1–2 days	3–4 days	5–6 days	Every day
Score	0	1	2	3	4

POEM Uses Self-assessment of the Frequency of Symptoms Identified by Patients to be Most Important¹

POEM: Patient-Oriented Eczema Measure (range 0–28)^{1,2}
Over the last week, on how many days has your skin been...

1. Itchy?
2. Bleeding?
3. Weeping or oozing?
4. Cracked?
5. Flaked off?
6. Dry or rough?
7. Over the last week, on how many days has your sleep been disturbed?

Response	No days	1–2 days	3–4 days	5–6 days	Every day
Score	0	1	2	3	4

Maximum score

28

0–2=clear or almost clear²
3–7=mild eczema
8–16=moderate eczema
17–24=severe eczema
25–28=very severe eczema

The DLQI Asks Patients to Assess how Their Skin Condition Affects 10 Different Aspects of Life^{1,2}

Over the last week, how much has your skin problem affected your life?



The DLQI Asks Patients to Assess how Their Skin Condition Affects 10 Different Aspects of Life^{1,2}



Over the last week, how much has your skin problem affected your life?

Itchy, sore, painful/stinging skin

Embarrassed, self-conscious

Shopping, garden or home activities

Clothes worn

Social or leisure activities

Sport

Work or studying

Personal relationships

Sexual difficulties

Treatment issues

Response	Score
Very much	3
A lot	2
A little	1
Not at all	0
Not relevant	0

DLQI, Dermatology Life Quality Index.
1. Finlay AY, et al. *Clin Exp Dermatol*. 1994;19(3):210-216. 2. Hongbo Y, et al. *J Invest Dermatol*. 2005;125(4):659-664.

The DLQI Asks Patients To Assess how Their Skin Condition Affects 10 Different Aspects of Life^{1,2}



Over the last week, how much has your skin problem affected your life?

Itchy, sore, painful/stinging skin

Embarrassed, self-conscious

Shopping, garden or home activities

Clothes worn

Social or leisure activities

Sport

Work or studying

Personal relationships

Sexual difficulties

Treatment issues

Response	Score
Very much	3
A lot	2
A little	1
Not at all	0
Not relevant	0

30

Maximum score

0–1=no effect
2–5=small effect
6–10=moderate effect
11–20=very large effect
21–30=extremely large effect on patient’s life²

DLQI, Dermatology Life Quality Index.
1. Finlay AY, et al. *Clin Exp Dermatol*. 1994;19(3):210-216. 2. Hongbo Y, et al. *J Invest Dermatol*. 2005;125(4):659-664.

George's DLQI Score Indicates That AD has an Extremely Large Effect on his Life



DLQI: Dermatology Life Quality Index (range 0–30)

Over the last week, how much has your skin problem affected your life?

1. Itchy, sore, painful/stinging: **3 (very much)**
2. Embarrassed or self-conscious: **3 (very much)**
3. Shopping, home/garden activities: **2 (a lot)**
4. Clothes: **3 (very much)**
5. Social or leisure activities: **3 (very much)**
6. Sport activities: **3 (very much)**
7. Working/studying: **3 (very much)**
8. Relationships with friends or relatives: **2 (a lot)**
9. Sexual difficulties: **2 (a lot)**
10. Treatment issues: **3 (very much)**

DLQI score

27

ASSESSMENTS

Pruritus

Sleep disturbance

Quality of life

DLQI subscores are exemplary based on the total DLQI score provided by Professor Amerio.
Case based on hypothetical patient.

George's DLQI Score Indicates That AD has an Extremely Large Effect on his Life



DLQI score

27

21–30=extremely large effect on patient's life¹

DLQI: Dermatology Life Quality Index (range 0–30)

Over the last week, how much has your skin problem affected your life?

1. Itchy, sore, painful/stinging: **3 (very much)**
2. Embarrassed or self-conscious: **3 (very much)**
3. Shopping, home/garden activities: **2 (a lot)**
4. Clothes: **3 (very much)**
5. Social or leisure activities: **3 (very much)**
6. Sport activities: **3 (very much)**
7. Working/studying: **3 (very much)**
8. Relationships with friends or relatives: **2 (a lot)**
9. Sexual difficulties: **2 (a lot)**
10. Treatment issues: **3 (very much)**

ASSESSMENTS

Pruritus

Sleep disturbance

Quality of life

DLQI subscores are exemplary based on the total DLQI score provided by Professor Amerio.
Case based on hypothetical patient.

George Experiences Substantial Burden From AD, Which may not be Reflected From Assessing his Signs Alone




EASI:	18.3	Moderate (Range: 0–72)
SCORAD:	58.3	Severe (Range 0–103)
Pruritus NRS:	9	Severe (Range: 0–10)
SCORAD VAS itch:	9.9	Severe (Range: 0–10)
SCORAD VAS sleep:	9	Severe (Range: 0–10)
DLQI:	27	Extremely large effect (Range: 0–30)


Case based on hypothetical patient.

AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema and Severity Index; NRS, Numerical Rating Scale; SCORAD, SCORing Atopic Dermatitis; VAS, visual analogue scale.

Multiple Assessment Tools are Available but no Single Score Captures the Diverse Signs, Symptoms, and QoL Impact of AD



Multiple Assessment Tools are Available but no Single Score Captures the Diverse Signs, Symptoms, and QoL Impact of AD



The ADCT is a new Patient-administered Tool That Assesses QoL and Helps Track Disease Control Over Time¹⁻⁴

SCORING AND INTERPRETATION²⁻⁴

Overall severity
of symptoms



Frequency of
intense episodes
of itching



Intensity
of bother (QoL)



Frequency
of sleep impact



Intensity
of daily activities
impact



Intensity
of mood or
emotions impact



24

Maximum (worst) score

ADCT, Atopic Dermatitis Control Tool; QoL, quality of life.

1. Williams HC, et al. *J Allergy Clin Immunol*. 2022;149(6):1899-1911. 2. Pariser DM, et al. *Curr Med Res Opin*. 2020;36:367-376.

3. ADCT patient form. https://www.adcontroltool.com/-/media/ems/conditions/dermatology/adct/files/pdf/uk%20english/adct_patient%20form_tearpad_au2.0-mktg_eng-gb.pdf. Accessed October 2022.

4. ADCT HCP Information card. https://www.adcontroltool.com/-/media/ems/conditions/dermatology/adct/files/pdf/uk%20english/adct_hcp%20information%20card_flashcard_au2.0-mktg_eng-gb.pdf. Accessed October 2022.

The ADCT is a new Patient-administered Tool That Assesses QoL and Helps Track Disease Control Over Time¹⁻⁴

SCORING AND INTERPRETATION²⁻⁴

Overall severity
of symptoms



Frequency of
intense episodes
of itching



Intensity
of bother (QoL)



Frequency
of sleep impact



Intensity
of daily activities
impact



Intensity
of mood or
emotions impact



Point-in-time
control status

Changes in control
status over time



24

Maximum (worst) score

Recommended by HOME
for measuring long-term control
in clinical trials¹

ADCT may also be useful
in routine practice⁴

ADCT, Atopic Dermatitis Control Tool; HOME, Harmonising Outcome Measures for Eczema; QoL, quality of life.

1. Williams HC, et al. *J Allergy Clin Immunol*. 2022;149(6):1899-1911. 2. Pariser DM, et al. *Curr Med Res Opin* 2020;36:367-376.

3. ADCT patient form. https://www.adcontroltool.com/-/media/ems/conditions/dermatology/adct/files/pdf/uk%20english/adct_patient%20form_tearpad_au2.0-mktg_eng-gb.pdf. Accessed October 2022.

4. ADCT HCP Information card. https://www.adcontroltool.com/-/media/ems/conditions/dermatology/adct/files/pdf/uk%20english/adct_hcp%20information%20card_flashcard_au2.0-mktg_eng-gb.pdf. Accessed October 2022.

RECAP is a new, Seven-item, Patient- or Caregiver-reported Outcome Measure of Eczema Control in the Past Week¹⁻³

SCORING AND INTERPRETATION²

How eczema
has been



Itchy skin



Intensely
itchy skin



Sleep disturbance



Getting in way
of daily activities



Affecting how
been feeling



Acceptability
of eczema



28

Maximum (worst) score

RECAP is a new, Seven-item, Patient- or Caregiver-reported Outcome Measure of Eczema Control in the Past Week¹⁻³

SCORING AND INTERPRETATION²

How eczema
has been



Itchy skin



Intensely
itchy skin



Sleep disturbance



Getting in way
of daily activities



Affecting how
been feeling



Acceptability
of eczema



Point-in-time
control status

Changes in control
status over time



28

Maximum (worst) score

Recommended by HOME
for measuring long-term control
in clinical trials¹

RECAP may also be useful
in routine practice^{2,3}

SUMMARY

- The full impact of atopic dermatitis cannot be estimated based on skin signs alone
- Burden of atopic dermatitis includes multiple factors – key among these are itch, pain, sleep, and quality of life
- Structured assessment of atopic dermatitis that measures signs, symptoms, QoL, and long-term disease control should be the goal in everyday clinical practice